Biotechnology
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis
Key Highlights * TGA has granted provisional designation for new drug Lurbinectedin based on encouraging Phase 2 results and high unmet medical need * A marketing application has now been accepted by the TGA under provisional evaluation pathway * Lurbinectedin has received priority review u...
2020-06-03 14:30
1334
Firmenich Appoints Boet Brinkgreve as President Ingredients
GENEVA, June 2, 2020 /PRNewswire/ -- In order to strengthen Firmenich industry leadership in ingredients and drive a new era of excellence, Firmenich, has appointed Boet Brinkgreve to President of Ingredients, effectiveJune 1st, 2020. Boet will continue to report directly to Firmenich CEO,Gilbert...
2020-06-02 23:41
1698
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced ...
2020-06-01 07:30
1666
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the research results of TY...
2020-06-01 07:30
1753
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of TYVYT® (sin...
2020-06-01 07:30
2454
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
SUZHOU, China and ROCKVILLE, Md., May 31, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company presented fo...
2020-05-31 20:00
2061
I-Mab Announces Upcoming Participation at June Conferences
SHANGHAI and GAITHERSBURG, Md., May 29, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical ...
2020-05-29 20:00
5967
Seaweed Extract Offers Hope for Influenza A
CAMBRIDGE, Australia, May 28, 2020 /PRNewswire/ -- Australian scientists have revealed that a natural compound found in seaweed may reduce the effects of severe cases of Influenza A. Fucoidan is a highly bioactive compound found naturally in brown seaweed and well known for its diverse therapeu...
2020-05-28 15:30
1024
IntegriCulture Inc. Closes Series A Fundraising Round Led by Beyond Next Ventures at JPY800 Million
TOKYO, May 28, 2020 /PRNewswire/ -- IntegriCulture Inc. has completed a Series A fundraising round ofJPY800 million (USD7.4 million) backed by Beyond Next Ventures, NH Foods, AgFunder and other investors. The cumulative amount raised stands aboutJPY1.1 billion (USD10.2 million). (Logo: https://...
2020-05-28 13:00
1917
Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies
SUZHOU, China, May 27, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery,development and manufacturing of antibody-based therapeutics, announced today results reported for the first time from a Phase 1...
2020-05-27 23:00
1089
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets
AMBLER, Pa., May 25, 2020 /PRNewswire/ -- Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's Du...
2020-05-25 22:00
1415
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
LONDON and SONGDO, South Korea, May 21, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK's innovative biopharmaceutical therapies. Under the terms of th...
2020-05-22 07:11
6278
Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II
SUZHOU, China, May 21, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing, today announced that it will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal ...
2020-05-21 23:00
1430
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction
BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today declared that Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan"), China Biolog...
2020-05-21 04:45
11215
China Biologic Reports Financial Results for the First Quarter of 2020
BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the first quarter of 2020. First Quarter ...
2020-05-21 04:30
10527
VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
AUSTIN, Texas, May 20, 2020 /PRNewswire/ -- VolitionRx Limited
2020-05-20 20:45
10737
WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform
PHILADELPHIA, May 18, 2020 /PRNewswire/ -- WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advanced therapies industry, announced today the expansion of its service capabilities to offer a fully int...
2020-05-18 21:00
1808
I Peace, Inc. Begins Clinical-Grade Induced Pluripotent Stem Cells Custom Manufacturing Service
PALO ALTO, Calif., May 15, 2020 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe ), aPalo Alto-based biotech start-up focusing on Nobel Prize-wining technology "induced pluripotent stem cell (iPSC)" began manufacturing clinical-grade iPSCs. We are now officially taking orders for custom manufacturi...
2020-05-16 01:00
2523
Happiness Biotech Announced Innovative Cultivation Technology of Lucidum
NANPING, China, May 13, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company has successfully developed an innovative cultivation technology of lucidum, which...
2020-05-13 20:00
4451
China Biologic Products to Report First Quarter 2020 Financial Results
BEIJING, China, May 12, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its first quarter 2020 financial res...
2020-05-12 20:30
9448
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 314 media titles]
2024-05-07 08:00
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 289 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
China-Serbia forum highlights community with shared future for mankind
[Picked up by 245 media titles]
2024-05-01 11:39
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
12290
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
8529
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
8064
